SK1-I

• UNSPSC Description:

  SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 μM[1]. SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity[2].

• Target Antigen:

  SphK

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sk1-i.html

• Purity:

  98.47

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC[C@H]([C@H](/C=C/C1=CC=C(C=C1)CCCCC)O)NC

• Molecular Weight:

  277.40

• References & Citations:

  [1]Melissa R Pitman, et al. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets. 2010 Jun;10(4):354-67.|[2]Santiago Lima, et al. TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition. Autophagy. 2018;14(6):942-957.|[3]Fiona H Greig, et al. Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse. Eur J Pharmacol. 2019 Jan 5;842:1-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1072443-89-0